Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

Congratulations to our own VP, Head of #Legal @RobinWalker for being honored as one of Mass. Lawyers Weekly’s (@masslw) 2019 In-House “Leaders in the Law” https://t.co/cb8AxycbeY #LeadersintheLaw

Thanks to the @STATNews #Biotech team for hosting The Readout Live at #JPM19. Here's our CEO Jim Burns catching up with @damiangarde on our #geneediting work and future treatments of #geneticdisease #JPMHC19

See us on Twitter